diagnosed medulloblastoma at our institution; these patients comprise this retrospective analysis. Each patient was treated by neurosurgeons, neurooncologists, and radiation oncologists.
Patient Characteristics
Patients ranged in age from 16 to 54 years with a median age of 21 years. There were 16 women and 11 men. The most common presenting symptoms were headache (93%), nausea and vomiting (78%), and gait instability (56%). There were 3 cases of cranial nerve palsies and 2 cases of torticollis at presentation. The median duration of symptoms was 9 weeks (range 2-43 weeks; 11 weeks for the 16 patients with midline lesions and 9 weeks for the 11 patients with lateral lesions). The median KPS score before surgery was 70 (range 50-90).
Initial neuroimaging consisted of CT scanning of the brain in 7 patients before 1986, and CT scanning and MR imaging in 20 patients since 1986. Hydrocephalus was present in 16 patients (11 cases with midline location and 5 cases with lateral location).
Surgical Treatment and Outcome
Five patients required placement of a ventriculoperitoneal shunt before tumor surgery. Tumor surgery consisted of a suboccipital craniectomy with resection of as much of the tumor as the surgeon considered prudent at the time. The extent of resection was based on the surgeon's assessment at the time of the operation and a review of the postoperative CT or MR images. Twenty-one patients had a gross-total resection, 2 had a subtotal resection (≥ 90% or when there were uncertainties about brainstem invasion), 1 had an incomplete resection (< 90%), and 3 had only a biopsy. Perioperative death consisted of 1 sudden unexplained death 10 days after complete resection. One patient experienced CSF leakage. Immediate postoperative clinical status showed functional improvement in 21 patients, no change in 4, and worsening in 1.
Histological Examination
All pathology slides were reviewed by a neuropathologist (S.S.) who had no knowledge of the patients' clinical course. Six patients (22%) had the desmoplastic variant: 3 patients had a lateral tumor (desmoplastic/lateral tumor ratio 27%) and 3 patients had a midline tumor (desmoplastic/midline tumor ratio 19%). The remaining 21 patients presented with classic medulloblastoma.
Tumor Staging
Each patient underwent staging according to the classic Chang system 11 definitions for tumor (T) and metastasis (M) parameters (Table 1) . The extent of spinal disease was assessed using MR imaging in 16 patients (preoperatively in 1). The cytological evaluation of CSF was conducted by performing a lumbar puncture after tumor resection and histopathological diagnosis of medulloblastoma in 25 patients. Two patients did not undergo CSF evaluation: 1 patient, whose status of metastasis was unknown (Stage MX), died suddenly 10 days after surgery of an unexplained cause, and the other had tonsillar herniation and spinal metastases (classified as Chang Stage M3) that rendered CSF subtraction by lumbar puncture impossible. Cytological analysis was negative in the remaining 25 patients, even in those with medulloblastomas classified as Stage M2. No patient presented with symptoms of systemic metastasis at diagnosis, but a complete evaluation was not routinely performed. The preoperative tumor stage showed 4 tumors with brainstem invasion (Chang Stages T3b and T4). Standard-risk patients were those whose tumor was confined to the primary area and who had undergone a gross-total resection. High-risk patients were those who had less than a gross-total resection of the primary lesion and those who had evidence of tumor dissemination. The patient with Chang Stage MX medulloblastoma, who did not undergo a complete evaluation of the spinal axis, was included in the high-risk group. Twenty patients were assigned to the standard-risk group and 7 to the high-risk group. With the exception of 1 patient, those whose tumors did not invade the brainstem and who had no metastasis underwent complete tumor resection.
Adjuvant Treatment
All patients, with the exception of the one who died suddenly after surgery, received external-beam radiotherapy to the entire craniospinal axis as part of the curative treatment at our institution. No patient had treatment interrupted by radiation-related toxicity. The median interval from surgery to the initiation of radiotherapy was 45 days (range 19-195 days). The median intervals from surgery to radiotherapy for patients who did and did not receive chemotherapy before radiotherapy were 133 days (range 87-195 days) and 39 days (range 19-122 days), respectively. The median dose to the entire brain was 30 Gy (range 24-54 Gy), to the posterior fossa 54 Gy (range 50-60 Gy), and to the spine 30 Gy (range 24-39.6 Gy).
Seven patients received primary (preradiotherapy) chemotherapy after tumor surgery. The types of chemotherapy were 8 drugs in 1 day (8-in-1) in 2 patients (2 cycles each), VACA in 2 patients (2 and 4 cycles), intrathecal methotrexate plus vincristine/lomustine, carboplatin/VP-16 (3 cycles), and cisplatin/VP-16 (3 cycles). Five patients who received chemotherapy presented with more advanced disease or incomplete resection of their tumors, and 2 were standardrisk patients (Stage T3aM0 and T2M0 medulloblastomas).
Statistical Analysis
The overall survival was calculated from the date of the first surgery to the date of death or to last follow-up for living patients (censored observation). Event-free survival was calculated from the date of the first surgery to the date of recurrence or tumor progression on neuroimages or to the date of last follow-up without progression (censored). Survival probabilities were estimated using the KaplanMeier method, 28 and the 95% CIs were calculated using the Rothman formula. 42 The log-rank test was used to assess the significance of the following prognostic variables: age (≤ 21 years vs > 21 years), sex, duration of symptoms (≤ 9 vs > 9 weeks), KPS score at presentation ( (1977-1985 vs 1986-1996 vs 1997-2005) . Univariate analysis was performed to identify prognostic variables for overall survival and progression-free survival. Independent prognostic factors were identified by multivariate regression analysis (Cox proportional hazards regression model). 16 Statistical analysis was performed using SPSS 15.0 software for Windows (SPSS, Inc.), and probability values < 0.05 were considered to be statistically significant.
Questionnaires on quality of life (Medical Outcomes Study SF-36 6, 46 ) and cognition (Mini-Mental State Examination), use of medication, presence of comorbidity, and social status were studied for the patients alive at the latest evaluation. The SF-36 questionnaire contains 36 questions examining several aspects of general well-being during the previous 4 weeks. The 36 questions are organized into 8 scales (physical functioning, physical problems, bodily pain, social functioning, general mental health, emotional problems, vitality, and general health perceptions), which are linearly converted to a scale of 0-100. Higher scores represent better quality of life.
Results
The median follow-up duration from diagnosis was 8.6 years (range 0-25.5 years). At the end of follow-up, 15 patients were alive, 11 patients had died of recurrence, and 1 patient had died in the perioperative period. The 5-year overall survival rate for the entire population was 81% (95% CI 63-92%), and the 10-and 20-year overall survival rates were 62% (95% CI 42-79%) and 43% (95% CI 23-69%), respectively ( Fig. 1) . The Kaplan-Meier estimated median overall survival time was 17.7 years (95% CI 1.0-34.3 years). The 5-year event-free survival (EFS) rate was 72% (95% CI 52-86%), and the 10-and 20-year EFS rates were 57% (95% CI 37-75%) and 43% (95% CI 20-70%), respectively (Fig. 1) . The Kaplan-Meier estimated median eventfree survival time was 17.9 years (95% CI 0-36.8 years).
Statistical Analysis of Prognostic Factors
Analysis of prognostic variables for overall and eventfree survival by univariate analysis is summarized in Table   2 . We did not identify the prognostic value of age, duration of symptoms, KPS score at presentation, hydrocephalus, tumor location, brainstem involvement, extent of resection, histological subtype, primary chemotherapy, or risk group. The period of first presentation was a prognostic factor neither for overall survival nor for event-free survival (Fig. 2) .
Prognostic factors that were significant for overall survival by univariate analysis included sex (p < 0.004) ( Fig. 3 ) and M stage (p < 0.002) (Fig. 4 ). Sex and M stage were also significantly associated with event-free survival (p < 0.011 and p < 0.005, respectively). At 5 years, 87% of patients with a Stage M0 metastasis were estimated to be alive and 81% disease free, while none of the 3 patients with Stage M2 and M3 metastases have reached 5 years (the 2 patients with Stage M2 died before this point, and at the latest evaluation, the patient with Stage M3 was free of disease 3.7 years after diagnosis).
Multivariate analysis confirmed the independent prognostic value of sex and M stage, and identified the period of presentation as a third independent prognostic factor for overall and event-free survival times. The ORs and 95% CIs are presented in Table 3 .
Tumor Recurrence
A total of 18 recurrences have been observed in 11 patients (41%) ( Table 4 ). The median time to first recurrence was 4.2 years (range 0.7-18 years). Overall survival was strongly correlated with recurrence (p < 0.0001) (Fig.  5 ). All patients in whom the tumor recurred have died. Only 1 patient's tumor recurred after a period of time corresponding to his age; the other tumors recurred much more quickly (< 8.5 years). This patient was 18 years old at the first presentation, and the tumor first recurred 18 years later exactly. Attempts at salvage treatments with surgery, radiotherapy, chemotherapy, or a combination of these were carried out for 10 of the 11 patients who experienced tumor recurrence, but the results of salvage therapy for recurrent disease have been poor in the long term. The Kaplan-Meier estimated median survival time after diagnosis of recurrence was 2.5 years (95% CI 1.8-3.2 years). Eight patients whose tumors recurred had postoperative craniospinal radiotherapy alone at first presentation, and 3 patients had preradiotherapy chemotherapy because of advanced disease (1 patient following the 8-in-1 protocol, 1 with VACA [2 cycles], and 1 following an old protocol of intrathecal methotrexate (Stage T2M0). The remaining 4 patients who have had preradiotherapy chemotherapy did not experience recurrence (3 patients with advanced disease and 1 patient with standard-risk disease).
Quality of Life
Fifteen patients alive and without evidence of disease at last follow-up were available for late toxicity evaluation (median follow-up 10.0 years, range 2.8-25.5 years). Among these 15 patients, 8 were asymptomatic and had a normal life, 4 had minor chronic fatigue but were capable of working full-time (KPS score of 90), and 3 were symptomatic (persistent cerebellar syndrome that was present before surgery), with KPS scores of 50-60, and required assistance. Results of the SF-36 questionnaire were as follows: median physical functioning score 100 (range 0-100), median physical problems score 100 (range 0-100), median bodily pain score 100 (range 10-100), median social functioning score 100 (range 0-100), median general mental health score 76 (range 8-88), median emotional problems score 100 (range 0-100), median vitality score 55 (range 0-75), and median general health perceptions score 80 (range 0-100). The scores obtained on the Mini-Mental State Examination were 30 of 30 for 10 patients; 29 for 2 patients; and 28, 26, and 22 for the 3 symptomatic patients. All the patients had occipital alopecia. A patient was treated for a vesiculopapillary carcinoma of the thyroid 7 years after craniospinal radiotherapy and is still alive without any sign of disease. This was the sole case of a supposed second malignancy. Routine endocrine assessments were not performed for all patients, but no patient showed evidence of pituitary dysfunction requiring hormonal supplements. Three patients had children 2, 15, and 20 years after surgery.
Discussion

Population Study
This retrospective study reflects the clinical experience with treatment of adults with primary cerebellar medulloblastoma at 1 institution over a 30-year time period. The definition of "adult" varies from author to author, but most series include patients of ≥ 16 years in the adult Moreover, patients > 16 years were treated at our institution during this period using adult protocols. Although a retrospective analysis has some restrictions, a single-institution study has the advantages of uniformity of staging and treatment for each time period, and availability of more detailed and accurate patient-, disease-, and treatment-related information.
The patient population structure was similar to that in previous studies for age, symptoms, duration of symptoms, KPS score, and hydrocephalus at presentation. 1, 4, 10, 22, 31, 32, 38, 40 The distribution of histological variants was also comparable to that reported by other authors, 1, 7, 10, 19, 24, 26, 31, 34, 36, 38, 43 with predominance of the classic histological phenotype. However, our population showed some characteristics different from other series. We observed a female preponderance, unlike most previous reports that described a male preponderance, as in childhood. 1, 3, 4, 7, 8, 10, 15, 19, 26, 32, 33, 43 This female preponderance is unusual but not exceptional as it has also been reported in several other studies. 14, 22, 24, 38 Moreover, despite the fact that our retrospective study began in the late 1970s before the modern era of neuroimaging and surgical tools, we observed that a gross-total removal of the primary tumor was achieved in 78% of all the patients, and in 95% of patients whose tumors did not invade the brainstem or the surrounding structures. These findings contrast with other authors' reports of complete resection in about half of the patients. 10, 19, 22, 24, 26, 31, 33, 36, 45 For many years, our general surgical principle has been to attempt as complete a resection of the tumor as possible, but it was also guided by what the surgeon considered prudent at the time: no attempts were made to remove the tumor from within the brainstem in cases of infiltration into the floor of the fourth ventricle or the cerebellar peduncles. This series also demonstrated that adult patients with medulloblastoma generally present with symptoms and signs indicating a posterior fossa lesion, and that the majority of patients have disease limited to the posterior fossa at the time of initial staging. None of our patients had extraneural disease at diagnosis. Extraneural metastases are so unusual that routine systemic evaluation of asymptomatic patients is of very low yield and probably unwarranted in this disease.
Survival Rate
This study documents high overall survival rates (median 17.7 years; 81 and 62% at 5 and 10 years, respectively) that compare well with other recent series of patients with adult medulloblastoma. 1, 4, 5, 7, 10, 26, 31, 33, 36 The best outcomes from medulloblastoma to date are from Kunschner et al., 31 who reported a 5-year overall rate of 84% for 28 adults treated between 1978 and 1998. The event-free survival rates (median 17.9 years; 72 and 57% at 5 and 10 years, respectively) in the present study are also within the published range. Survival has improved in recent decades since 5-year survival rates of 50% 3, 25, 29, 30, 39 to 60% 19,27,44 were reported in studies published since the end of the 1980s. Our study reflects the current tendency toward an improvement in survival rates. The overall survival rate did not change at 5 years between the first period (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) ) before the era of MR imaging (86%) and the last period (1997-2005) (85%), but it improved at 10 years from 57 to 71% between the same periods, and at 20 years from 29 to 57% between 1977-1986 and 1987-1996. The difference was more obvious concerning the event-free survival times as we observed improvement of survival rates from 57 to 85% at 5 years and from 29 to 74% at 10 years between the first and last periods. This observation was also confirmed by the multivariate analysis that identified the period of presentation as an independent prognostic factor for overall and event-free survival times. The high overall survival, despite the number of recurrences, suggests that adult medulloblastoma remains responsive to therapy even after first relapse. Despite the small number of patients, salvage treatment with surgery, radiotherapy, and chemotherapy appears to have a role in recurrent disease in that several patients showed durable responses after recurrence.
Prognostic Factors
The prognostic factors in childhood medulloblastomas have been extensively studied but have varied during the last 20 years. The current consensus seems to be that in patients < 2 years of age, metastatic disease, brainstem, or fourth ventricular floor involvement are correlated with a worse outcome. 35, 48 In the adult population, sex significantly affected survival in our study: female patients had better overall and event-free survival times than male patients. This impact has already been reported in other adult series 12, 18, 32, 40 as well as in children. 13, 45, 47 Others 1, 3, 4, 10, 25, 26, 36 have found that sex did not affect survival or, on the contrary, noted better outcome for male patients. 23 Some explanations for these findings have been suggested as follows: a behavior of medulloblastoma intrinsically different between sexes, favoring a more indolent, well-localized, and more easily resectable form in female patients; the presence of female hormones, which may provide protection against tumor recurrence; and the precocious puberty induced by therapy that confers a survival advantage in children as well as the fact that girls were usually more sensitive to therapy. 32, 45, 47 However, we have not been able to determine particular features of the tumors in our female patients that might have suggested such different behavior. This sex-based difference for survival and disease control remains an enigma and should be viewed cautiously because of the small sample size of our series. On the other hand, it sustains the clinical axiom in oncology that "girls are good, boys are bad," and may be evaluated in the next prospective clinical trials.
Patients with metastases at presentation, although not very common, have an unfavorable short-term prognosis. In the current study, only 3 patients had evidence of metastases at diagnosis, a level similar to that observed in other series. 1, 7, 30, 31 Among these patients, 2 had early relapse in the spinal axis despite more aggressive therapy. In agreement with other reports on adults 1, 4, 19, 32, 36, 40 and children, 17, 37, 48 we found that the presence of metastatic disease at presentation was an important prognostic factor for overall and event-free survival times. In a larger multicenter series, 7 metastatic disease did not appear to be correlated with a worse prognosis, but data were available for only 61% of the patients, and half of the patients with Stage M0 medulloblastomas received chemotherapy either before or after, or both before and after, radiotherapy. Those authors suggested that the usual high dose (30-36 Gy) of radiation administered to the entire brain and spinal axis in adult patients, whether metastatic disease is present, could reduce the prognostic significance of widespread disease. Nevertheless, we are convinced that the presence of either microscopic or macroscopic metastases at presentation remains one of the most important prognostic factors in adult medulloblastoma as in the pediatric population, and that a careful systematic staging is mandatory for this tumor with both neuroimaging and CSF analysis by lumbar puncture, and systemic evaluation if symptoms are present.
Other patient characteristics such as brainstem insion, incomplete resection, and high-risk group, previously reported to reach significance as unfavorable prognostic variables, especially among the pediatric population, were not found to reach significance in our study. There are a few studies that have evaluated survival stratified on the basis of risk evaluation in adults with medulloblastoma. 5, 31, 36, 40 Our impression was similar to that of Brandes et al. 5 and Kunschner et al. 31 who observed a comparable outcome for both standard-and high-risk groups in terms of overall or event-free survival. The fact that all the patients did not undergo early postoperative MR imaging in this retrospective study, that patients with high-risk disease had more aggressive therapies, and that therapies were not standardized may have confused our results. Like others, 4, 5, 26 we are convinced that adjuvant chemotherapy reduces the risk of recurrence and death in patients with advanced disease, in other words the high-risk group.
The value of clinical status at diagnosis, tumor location, or histology also remains unclear as discrepancies were observed in most of the studies. 4, 7, 10, 24, 26, 36 The desmoplastic subtype has been observed more frequently in the adult than in the pediatric population. 21, 23, 43 It was suggested as one of the explanations for the better prognosis reported in the adult population because of lower growth rate parameters observed in the desmoplastic variant (decreased proliferation index and/or increased apoptotic index).
24,43
Not everyone will agree on this feature, but this histological distinctiveness should be kept in mind for the next trials as desmoplastic subtype has already been associated with a genetic disorder and a better outcome in children. 2 
Tumor Recurrence
The pattern of failure seen in the group of 27 patients exhibits some interesting observations. The first point is that recurrence did not develop most often in the posterior fossa in our series, contrary to what has been described in other studies. 3, 10, 19, 24, 27, 32, 40, 44 We observed only 1 supratentorial metastasis in an initial recurrence, in accordance with previous reports that recorded this as a rare location. 1, 19, 25, 26, 32 On the other hand, we observed, as other authors have, 1, 10, 29, 31, 38 that the incidence of extraneural metastasis at recurrence was proportionally high. This seems to be characteristic of adults as opposed to children and may represent a biological difference between the tumor found in adults and that found in children. 31 It may also indicate that local tumor control has been brought about by radiotherapy alone, and that a systemic adjuvant treatment in the standard-risk group should be suggested to reduce the number of recurrences at a distance from the primary tumor. Indeed, the role of adjuvant chemotherapy in high-risk patients has been demonstrated in terms of risk of recurrence, delay of recurrence, and death, 4, 5 but it is still unidentified in standard-risk patients. This relatively high frequency of spinal and extraneural metastasis must also be taken into account for regular clinical evaluation of the patient during follow-up, and vigilance must be used concerning new symptoms, as recurrences may develop in isolation and at a distance from the posterior fossa although the primary tumor is under control.
The second point is that delayed recurrences were not particularly rare (median latency 4.2 years, range 0.7-18 years). This is also a characteristic of adult medulloblastoma, which has already been described, 5, 10, 25, 38 and is unlike childhood medulloblastoma where recurrences develop more rapidly. However, no exceptions to the Collins Law were observed, as only 1 of our patients suffered a recurrence after a period of time exactly equal to his age (18 years).
The third point is that all types of recurrence imply an unfavorable prognosis whatever the treatment (all patients who had recurrences have died). However, survival of patients suffering recurrence may be prolonged by several years by using aggressive treatment (median time to death after diagnosis, 2.5 years). Gamma Knife surgery has also been recently used in recurrent medulloblastoma with promising results and should be considered part of the range of therapeutic options. 20 It therefore appears possible to propose an optimum treatment in case of recurrence, taking into account the fact that other metastatic lesions may occur at different sites during the evolution of the disease. Spinal axis recurrence had the most unfavorable prognosis with the shortest delays before the appearance of metastases and the shortest survival times of all potential sites. Moreover unlike other authors 3 we observed a higher frequency of cervical recurrence.
The final point is that we do not deem it possible for the moment to define a typical profile for patients with medulloblastoma at risk for recurrence, be it for the stage of disease, tumor location, histological subtype, quality of resection, or postoperative treatment. There appear to be multiple interrelated factors influencing prognosis; this renders their identification difficult, and it is clear that we are still far from understanding all the biological characteristics of this tumor.
Conclusions
Long-term survival is possible in adults treated for cerebellar medulloblastoma. Surgery and postoperative craniospinal radiotherapy are the mainstay treatments for this disease. Prognostic factors vary from one study to another but prospective trials should continue to analyze classic factors such as sex, histological variants, or Chang staging. Metastasis seeding at presentation, although rare, is a poor prognostic factor for relapse. The very real possibility of delayed recurrence mandates close follow-up of all patients with this disease, with prompt evaluation of new symptoms. Recurrences should be treated with aggressive therapies as some patients may have sustained response. Adjuvant chemotherapy should be given to high-risk patients, but its role remains unclear in standard-risk adult medulloblastoma. The question remains whether adjuvant chemotherapy can reduce recurrences, particularly distant ones, and improve survival with an acceptable toxicity.
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